QALQONSIMON BEZ SARATONI: KELIB CHIQISH MEXANIZMLARI, ORGANLAR ZARARLANISHI, LABORATORIYA TASHXISI, DAVOSI VA PROFILAKTIKASI

Authors

  • Musulmonov Shoxruh Author
  • Shavkatova Xosiyat Avaz qizi Author

Keywords:

qalqonsimon bez saratoni, patogenez, MAPK, PI3K/AKT, BRAF V600E, tireoidektomiya, radioaktiv yod, maqsadli terapiya, laboratoriya tashxisi, profilaktika, asoratlar

Abstract

Dolzarbligi: Qalqonsimon bez saratoni bugungi kunda dunyo bo'ylab endokrin tizimning eng ko'p uchraydigan xavfli o'smasi bo'lib, yillik yangi kasallanish soni 586 000 dan oshib ketgan. So'nggi o'ttiz yil ichida kasallik chastotasi uch barobar ko'paygan. Kasallikning kelib chiqish mexanizmlari, asoratlari, tashxisi, davosi va profilaktikasini yaxlit o'rganish tibbiyot amaliyoti uchun muhim ahamiyat kasb etadi. Maqsad: Qalqonsimon bez saraton kasalligining molekulyar-genetik kelib chiqish mexanizmlari, organlar zararlanishi, laboratoriya va instrumental tashxis usullari, jarrohlik davolash, konservativ terapiya va profilaktikasini ilmiy adabiyotlar asosida tizimlashtirib taqdim etish. Usul: 2013–2026-yillar oralig'ida PubMed va Google Scholar ma'lumotlar bazalarida chop etilgan ilmiy adabiyotlar tahlil qilindi. Tanlov mezonlari: kliniko-morfologik, molekulyar va terapevtik ma'lumotlarni o'z ichiga olgan, ingliz va o'zbek tillarida nashr etilgan maqolalar.

References

(PubMed va Google Scholar, Vancouver uslubi, 2013–2026-yillar nashriyoti)

1. Prete A, Borges de Souza P, Censi S, Mian C, Barollo S, Morelli LM. Update on fundamental mechanisms of thyroid cancer. Front Endocrinol (Lausanne). 2020

11:102. doi:10.3389/fendo.2020.00102.

2. Carnazza M, Quaranto D, DeSouza N, Petrone A, Ciccone V. The current understanding of the molecular pathogenesis of papillary thyroid cancer. Int J Mol Sci. 2025

26(10):4646. doi:10.3390/ijms26104646.

3. Zhou C, Liu W, Zheng J, Wu Q, Ai Z. Molecular mechanisms of thyroid hormone signaling in thyroid cancer. Biomedicines. 2025

13(10):2552. doi:10.3390/biomedicines13102552.

4. Zhao S, Zhao Y, Wang G. Pathogenesis and signaling pathways related to iodine-refractory differentiated thyroid cancer. Front Endocrinol (Lausanne). 2024

15:1320044. doi:10.3389/fendo.2023.1320044.

5. Riesco-Eizaguirre G. BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity. Eur Thyroid J. 2025. doi:10.1530/ETJ-25-0225.

6. Liu L, Wei F. Mutation interactions of BRAF and TP53 define novel prognostic stratification in papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2025

16:1584618. doi:10.3389/fendo.2025.1584618.

7. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013

2013:965212. doi:10.1155/2013/965212.

8. Xu B, Ghossein R, Lane J, Tuttle RM, Ganly I. The utility of TERT promoter mutation detection in thyroid fine-needle aspiration. Cancer Cytopathol. 2020

128(5):366–374. doi:10.1002/cncy.22251.

9. Petre A, Ferrerons G, Sancho J, Oriola J, Mesa J, Biagetti B. Molecular pathology of poorly differentiated and anaplastic thyroid cancer. Endocr Pathol. 2021

32(1):68–84. doi:10.1007/s12022-021-09665-2.

10. Zablotska LB, Nadyrov EA, Rozhko AV, et al. Thyroid cancer after exposure to radioiodine in childhood and adolescence. Int J Cancer. 2021

148(8):1880–1892. doi:10.1002/ijc.33396.

11. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011

7(10):569–580. doi:10.1038/nrendo.2011.142.

12. Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016

375(11):1054–1067. doi:10.1056/NEJMra1501993.

13. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022

72(1):7–33. doi:10.3322/caac.21708.

14. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016

26(1):1–133. doi:10.1089/thy.2015.0020.

15. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007

28(7):742–762. doi:10.1210/er.2007-0007.

16. Tallini G, de Biase D, Durante C, et al. BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study. Mod Pathol. 2015

28(12):1587–1602. doi:10.1038/modpathol.2015.111.

17. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013

98(11):E1852–E1860. doi:10.1210/jc.2013-2292.

18. Censi S, Mian C, Barollo S, et al. TERT promoter mutation in thyroid carcinoma: a systematic review and meta-analysis. Eur J Endocrinol. 2020

183(1):1–12. doi:10.1530/EJE-19-0907.

19. Crocetti U, Bondi B, Orlacchio A, et al. Iodine intake as a risk factor for thyroid cancer. Eur Thyroid J. 2019

8(5):231–241. doi:10.1159/000502283.

20. WHO Classification of Tumours Editorial Board. WHO Classification of Tumours: Endocrine and Neuroendocrine Tumours. 5th ed. Lyon: IARC

2022. ISBN: 978-92-

Published

2026-05-08